Ultragenyx Pharmaceutical (RARE) Bank of America Global Healthcare Conference 2026 summary

Commercial performance and outlook

• Four commercialized products are expected to generate $730–$760 million in revenue this year, with CRYSVITA contributing $500–$520 million and showing single- to double-digit growth, though growth has leveled compared to previous years.

• Revenue guidance for the year is reaffirmed despite a slight quarterly miss, with expected sawtooth quarterly patterns and some lumpiness in Latin America due to large contracts.

• Profitability is targeted for 2027, relying on continued double-digit growth from current programs and potential new launches, with not all new launches required to achieve this goal.

• A cost savings program, including a 10% workforce reduction, is underway to support profitability, with R&D and SG&A expenses expected to decline as a percentage of revenue.

• Priority review vouchers (PRVs) from new approvals are expected to provide additional financial strength.

Angelman syndrome program updates

• Phase III data for Angelman syndrome is anticipated in the second half of the year, with long-term phase I/II data showing sustained efficacy and no new safety concerns.

• Primary endpoints for the trial are Bayley-4 cognition and MDRI, with alpha split between them to hedge regulatory risk and reflect clinical relevance.

• Patient and caregiver feedback emphasizes the importance of improvements across multiple domains, aligning with the MDRI endpoint.

• The patient population for phase III closely matches that of phase I/II, supporting confidence in data translation.

• If successful, the next steps include BLA submission and launch preparation, targeting a global addressable market of about 60,000 patients.

Gene therapy pipeline and launch readiness

• Two gene therapy programs, DTX401 (GSDIa) and UX111 (Sanfilippo), have PDUFA dates in the second half of the year, with DTX401's date on August 23.

• DTX401 addresses a high unmet need, aiming to replace burdensome cornstarch regimens with a therapy that targets the underlying metabolic defect.

• Launch planning for DTX401 leverages existing sales infrastructure, with pricing expected in the $1–$2 million range based on payer feedback.

• UX111 targets a smaller population (3,000–5,000), with pricing anticipated at $2–$4 million; both programs are supported by strong physician and patient community interest.

• Manufacturing and inventory for both gene therapies are prepared, with only minor sales force expansion planned to support launches.